Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The revised deal builds on the work Roche and Voluntis have done on data-driven improvements to symptom control in breast cancer patients.
The takeover will add a minimally invasive way of destroying obstructive prostate tissue to Boston Scientific’s urology business.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
Novartis foresees next-generation immunotherapies that use biodegradable implants and injectable systems to trigger long-lasting attacks on tumors.
J&J has until the middle of June to accept the offer for its blood glucose monitoring business.
Devicemaker Orthofix is acquiring Spinal Kinetics, which manufactures artificial cervical and lumbar discs, in a deal that could be worth up to $105 million.…
Antibiotic R&D funding partnership CARB-X is putting up the cash to cut the time it takes to learn what pathogen is responsible for a case of sepsis.
The change sets the collaborators up to forge ahead with efforts to improve the sensitivity of spinal muscular atrophy screening tests.
The upfront payment sets Qiagen up to develop cell-free DNA assays with Natera for the next decade.
The takeover will give Laborie control of devices for the treatment of overactive bladder and stress urinary incontinence.
Genomics giant WuXi NextCODE is partnering with Google Cloud to establish a global platform standard for using genome data to advance health worldwide.